When a Biotech Consulting Client Pays You in Warrants

Warrants received from clients don't have an obvious market price the way cash revenue does, and marking them at face value or ignoring them entirely both distort your own firm's valuation. Get warrants in privately held client companies appraised periodically, even roughly, rather than carrying them at whatever value made sense when the engagement was signed, since a client's fortunes can shift considerably between a warrant's grant date and your own next valuation. Bring that appraisal, however approximate, to your own valuation provider so warrant value isn't silently excluded or double-counted.

A single strong quarter driven by a trial hitting its endpoint or a regulatory milestone clearing doesn't represent your firm's normal earning pace, and neither does a quiet quarter between milestones. Ask your appraiser to work from a longer trailing view, ideally spanning at least one full milestone cycle for your typical engagement, and to note which portion of revenue is milestone-contingent versus fixed retainer, so the valuation doesn't overweight whichever quarter happened to include a payout.

When a promising engagement turns into a joint venture or a standalone entity, that new entity needs its own formation documents, its own cap table, and its own valuation dated to its own formation, not a line item tucked inside your consulting firm's existing equity plan. Blending them muddies both: your consultancy's own valuation gets distorted by an entity with a completely different risk profile, and the spinout's investors or acquirers eventually want to see clean, standalone governance history anyway.

A single consultancy issuing its first option grants to senior scientific staff fits Carta's straightforward workflow well. Once you're actively managing two or three spun-out entities alongside the parent consultancy, each with its own grants, board, and valuation calendar, Shareworks' multi-entity administration starts earning its more complex setup, since keeping several entities organized inside one lighter tool gets error-prone as the number grows.

Some firms fold the estimated value of client warrants directly into revenue when pricing their own option grants, which overstates the business if those warrants never convert to anything liquid. Keep warrant value visible to your appraiser as a distinct, separately disclosed asset rather than blended into revenue, so a defensible valuation doesn't rest partly on paper gains that may never materialize.

Before your next valuation engagement, hand your appraiser three things directly: a list of client warrants held with their grant dates and any recent appraisal, a breakdown of which contracts are milestone-based versus fixed retainer, and current status on any spinout entities and how their equity is separately tracked. Firms that wait for the appraiser to ask usually leave out at least one of these, and each omission is exactly the kind of gap that produces a valuation that doesn't hold up under later scrutiny.

Hand your appraiser these items before the engagement starts:

• A list of the client warrants you hold, with their grant dates and any recent appraisal of the privately held company behind each one.
• A breakdown of which contracts are milestone-based and which are fixed retainers, so lumpy revenue can be separated from steady revenue.
• The current status of any spinout entities and how their equity is tracked separately from your consultancy's own cap table.
• A request for a trailing view spanning at least one full milestone cycle for your typical engagement.

Say your consultancy is running three active engagements at once: one paying a flat monthly retainer, one paying milestone fees tied to a trial readout, and one that just spun out into its own joint venture with a client. Each creates a different question for your own valuation. The retainer engagement is straightforward, steady revenue that belongs in any trailing view without adjustment. The milestone engagement needs the timing treatment described above, normalized rather than annualized off whichever quarter the readout happens to land in. The spinout needs to come off your books entirely and get its own valuation once it's genuinely a separate entity.

Handled together in one valuation conversation, rather than as three separate afterthoughts, your appraiser gets a coherent picture instead of three data points that don't obviously reconcile. Bring a one-page summary of each active engagement's structure, retainer, milestone-based, or spun out, to every valuation refresh, and update it each time the engagement mix changes meaningfully. That habit alone catches most of the timing and entity-separation mistakes that otherwise only surface when someone questions the valuation later, usually at the worst possible moment, like during a spinout's own fundraising diligence.